Erythromycin treatment of acute and chronic urethritis, prostatitis and colpitis caused by Ureaplasma urealyticum and Chlamydia trachomatis.
This report concerns the treatment of 250 patients with acute or chronic urethritis or urethro-adnexitis which was caused by Ureaplasma urealyticum or Chlamydia trachomatis. The patients were treated with 2 x 1 g erythromycin daily for a period of 3 weeks and were examined 8 days after discontinuing treatment. The MIC and MBC values against erythromycin were determined in some of the isolated Ureaplasma and Chlamydia strains. For Ureaplasma urealyticum the MIC is approximately 0.5 mcg/ml and for Chlamydia trachomatis approximately 2.0 mcg/ml. The report covers therapeutic responses, the benefit of and reasons for long-term treatment, relapses and patients who did not respond to treatment.
D002690:Chlamydia Infections / Q000188:drug therapy*; D002692:Chlamydia trachomatis; D004305:Dose-Response Relationship, Drug; D004917:Erythromycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011472:Prostatitis / Q000188:drug therapy*; D014509:Ureaplasma; D014526:Urethritis / Q000188:drug therapy*; D014627:Vaginitis / Q000188:drug therapy*
D004917:Erythromycin